ArticleThe Journal of infection2022
SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Oral contraceptive usage among healthcare workers and its impact on COVID-19 booster vaccination immunogenicity.NPJ vaccines · 2026Article
- Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.Journal of clinical immunology · 2026Observational
- Association of COVID-19 vaccines and antibody response in individuals with prior Coronavirus infection.Scientific reports · 2026Article
- Estimating the Optimal COVID-19 Booster Timing Using Surrogate Correlates of Protection: A Longitudinal Antibody Study in Naïve and Previously Infected Individuals.Pathogens (Basel, Switzerland) · 2025Article
- Analysis of Cell Immunity for Children Infected with SARS-CoV-2 and Those Vaccinated against SARS-CoV-2 Using T-SPOTMicroorganisms · 2024Article
- Epidemiological and clinical perspectives of long COVID syndrome.American journal of medicine open · 2023Article
- Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity.Life (Basel, Switzerland) · 2023Article
- Enriched CXCR3The Journal of infection · 2023Article
- Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19.World journal of clinical cases · 2023Review
- The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics.Journal of molecular biology · 2023Article
- Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review.Infectious diseases and therapy · 2023Review
- Article
- Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management.Journal of clinical medicine · 2022Article
- Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers.Scientific reports · 2022Article
- Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2.The Journal of infection · 2022Article
- Comparison between an in-house SARS-CoV-2 ELISpot and the T-Spot® Discovery SARS-CoV-2 for the assessment of T cell responses in prior SARS-CoV-2-infected individuals.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Article
- Longevity of memory B cells and antibodies, as well as the polarization of effector memory helper T cells, are associated with disease severity in patients with COVID-19 in Bangladesh.Frontiers in immunology · 2022Article
- Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesFirst, to describe SARS-CoV-2 T cell and antibody responses in a prospective cohort of healthcare workers that suffered from mild to moderate COVID-19 approximately one year ago. Second, to assess COVID-19 vaccine-induced immune responses in these prior-infected individuals.
methodsSARS-CoV-2-specific T cell and anti-SARS-CoV-2-Spike-RBD immunoglobulin G (IgG) responses in blood were determined before COVID-19 vaccination with mRNA-1273, BNT162b2, Ad26.CoV2-S or ChAdOx1-S, two weeks after first vaccination, and after second vaccination.
results55 prior SARS-CoV-2 infected and seroconverted individuals were included. S1-specific T cell responses and anti-RBD IgG were detectable one year post SARS-CoV-2 infection: 24 spot-forming cells per 10
conclusionsBoth T cell and IgG responses against SARS-CoV-2 persist for up to one year after COVID-19. A second COVID-19 vaccination in prior-infected individuals did not further increase immune responses in comparison to one vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.